Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report

Immune checkpoint inhibitors (ICIs) provide substantial benefits to a small subset of patients with advanced cancer with mismatch repair deficiency (MMRD) or microsatellite instability (MSI), including patients with pancreatic ductal adenocarcinoma (PDAC). However, the long duration of ICI treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Shang-Hsuan, Chen, Bang-Bin, Kuo, Ting-Chun, Lee, Jen-Chieh, Yang, Shih-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792834/
https://www.ncbi.nlm.nih.gov/pubmed/36582237
http://dx.doi.org/10.3389/fimmu.2022.1077840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792834/
https://www.ncbi.nlm.nih.gov/pubmed/36582237
http://dx.doi.org/10.3389/fimmu.2022.1077840

Ejemplares similares